ABEONA THERAPEUTICS INC. (ABEO) — SEC Financial Statements & Analysis

ABEONA THERAPEUTICS INC. (ABEO) is a pharmaceutical preparations company, incorporated in DE. ABEONA THERAPEUTICS INC. trades on Nasdaq as: ABEO. ABEONA THERAPEUTICS INC. (ABEO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, ABEONA THERAPEUTICS INC. carries a market cap of $352.56M, a P/E ratio of -5.61x, a P/B ratio of 2.75x, a P/S ratio of 13.82x, an enterprise value of $311.32M, and an EV/EBITDA multiple of -3.85x. On profitability, it posts a gross margin of 67.07%, an operating margin of -327.64%, a net margin of -246.42%, a Return on Equity (ROE) of -43.13%, a Return on Assets (ROA) of -29.54%, and a Return on Invested Capital (ROIC) of -125.92%. Per share, it reports EPS of $-1.10, diluted EPS of $-1.10, free cash flow per share of $-1.43, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 550.69% year-over-year, net income growth of -209.86% year-over-year, and EPS growth of -201.15% year-over-year. On the balance sheet, it maintains a current ratio of 6.63x, a quick ratio of 6.32x, working capital of $139.77M, a debt-to-equity ratio of 0.40x, a debt ratio of 0.29, an interest coverage ratio of -25.25x, free cash flow of $-81.53M (TTM), and net debt of $-41.24M. Figures sourced from SEC EDGAR.

Market Cap

$352.56M

P/E TTM

-5.61x

EPS TTM

$-1.10

P/B TTM

2.75x

ROE TTM

-43.13%

ROA TTM

-29.54%

Debt To Equity

0.40x

Free Cash Flow TTM

$-81.53M

Net Revenue TTM Growth 1Y

550.69%

Data as of 2026-06-30 · Source: SEC EDGAR